Michael S Ip Selected Research

salicylhydroxamic acid (SHAM)

3/2022	Disease-modifying effects of ranibizumab for central retinal vein occlusion.
9/2012	Long-term effects of ranibizumab on diabetic retinopathy severity and progression.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael S Ip Research Topics

Disease

48	Macular Edema 05/2024 - 09/2002
38	Retinal Vein Occlusion 12/2023 - 09/2002
16	Diabetic Retinopathy (Retinopathy, Diabetic) 11/2023 - 09/2007
8	Macular Degeneration (Age-Related Maculopathy) 05/2024 - 10/2008
5	Hemorrhage 03/2022 - 09/2009
3	Inflammation (Inflammations) 03/2024 - 09/2010
3	Retinal Hemorrhage 03/2022 - 09/2010
3	Endophthalmitis (Ophthalmia) 05/2017 - 09/2007
3	Cataract (Cataracts) 12/2009 - 03/2009
2	Retinal Detachment (Retinal Detachments) 05/2024 - 12/2008
2	Retinal Vasculitis 03/2024 - 11/2023
2	Glaucoma 12/2021 - 12/2009
2	Stargardt Disease 10/2021 - 01/2020
2	Atrophy 10/2021 - 11/2006
2	Burns 01/2017 - 03/2013
2	Choroidal Neovascularization 01/2017 - 03/2013
2	Papilledema 12/2014 - 01/2011
2	Vitreous Hemorrhage 09/2012 - 12/2009
1	Proliferative Vitreoretinopathy 05/2024
1	Retinal Artery Occlusion 11/2023
1	Vascular Diseases (Vascular Disease) 01/2023
1	Epiretinal Membrane (Epiretinal Membranes) 03/2022
1	Microaneurysm 01/2021
1	Infertility (Sterility) 09/2019
1	Retinal Neovascularization 01/2018
1	Angle-Closure Glaucoma (Glaucoma, Angle Closure) 05/2017
1	Diabetes Mellitus 01/2017
1	Coronary Artery Disease (Coronary Atherosclerosis) 01/2017
1	Hypertension (High Blood Pressure) 01/2017
1	Disease Progression 09/2012
1	Dyslipidemias (Dyslipidemia) 01/2011
1	Edema (Dropsy) 05/2010
1	Telangiectasis (Telangiectasia) 01/2010
1	Retinoschisis (Retinoschisis, Juvenile) 12/2008
1	Retinal Perforations 12/2008

Drug/Important Bio-Agent (IBA)

32	Retinaldehyde (Retinal)IBA 05/2024 - 11/2006
21	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 05/2024 - 10/2008
20	afliberceptIBA 11/2023 - 09/2014
17	Bevacizumab (Avastin)FDA Link 10/2023 - 09/2014
16	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2021 - 09/2007
13	Triamcinolone (Aristocort)FDA Link 02/2011 - 07/2004
9	Valsartan (Vals)FDA Link 05/2024 - 05/2017
7	Ranibizumab (Lucentis)FDA Link 03/2022 - 09/2012
7	Fluorescein (Funduscein)FDA LinkGeneric 01/2022 - 09/2010
6	Triamcinolone Acetonide (Azmacort)FDA LinkGeneric 09/2015 - 09/2002
4	brolucizumabIBA 03/2024 - 01/2023
4	Biomarkers (Surrogate Marker)IBA 01/2023 - 01/2020
3	Propranolol (Inderal)FDA LinkGeneric 01/2018 - 03/2013
2	Silicone OilsIBA 05/2024 - 11/2009
2	salicylhydroxamic acid (SHAM)IBA 03/2022 - 09/2012
1	Retinal Pigments (Pigments, Visual)IBA 10/2021
1	2- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA 07/2021
1	Indicators and Reagents (Reagents)IBA 01/2021
1	EndotoxinsIBA 09/2019
1	Adrenergic Agents (Adrenergic Drugs)IBA 03/2013
1	Niacin (Nicotinic Acid)FDA LinkGeneric 01/2011

Therapy/Procedure

16	Therapeutics 12/2023 - 01/2004
7	Lasers (Laser) 01/2023 - 12/2008
6	Injections 03/2022 - 09/2007
6	Light Coagulation 02/2011 - 07/2008
5	Intravitreal Injections 09/2012 - 07/2004
3	Aftercare (After-Treatment) 01/2022 - 01/2019
3	Drug Therapy (Chemotherapy) 10/2016 - 10/2008
2	Vitrectomy 03/2022 - 09/2010
2	Laser Therapy (Surgery, Laser) 12/2021 - 12/2009
1	Intraocular Injections 03/2022
1	Intraperitoneal Injections 03/2013
1	Glycemic Control 07/2008
1	Antibiotic Prophylaxis 09/2007